A composition for the prevention or treatment of pulmonary fibrosis containing taurodeoxycholic acid or its pharmaceutically acceptable salt as an active ingredient

RU2024129974A3Pending Publication Date: 2026-07-10SHAPERON INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
RU · RU
Patent Type
Applications
Current Assignee / Owner
SHAPERON INC
Filing Date
2023-04-06
Publication Date
2026-07-10
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.

Claims

1. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis, containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

2. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 1, wherein taurodeoxycholic acid is a compound represented by the following chemical formula 2 .

3. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 1, wherein the pharmaceutically acceptable salt is a sodium salt.

4. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 1, wherein the composition reduces the expression of factors associated with pulmonary fibrosis.

5. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 4, wherein the factors associated with pulmonary fibrosis are COL1α1, α-SMA or PAI-1.

6. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 1, wherein pulmonary fibrosis is selected from the group consisting of idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, acute interstitial pneumonia, cryptogenic organizing pneumonia, interstitial lung disease associated with respiratory bronchiolitis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, interstitial pulmonary fibrosis and diffuse pulmonary fibrosis.

7. A pharmaceutical composition for the prevention or treatment of pulmonary fibrosis according to claim 1, further comprising one or more pharmaceutically acceptable carriers.

8. A functional health composition for preventing or improving pulmonary fibrosis, containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

9. A food composition for preventing or improving pulmonary fibrosis, containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

10. A method for the prevention or treatment of pulmonary fibrosis, comprising the step of administering to a patient taurodeoxycholic acid or a pharmaceutically acceptable salt thereof.

11. The use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as a pharmaceutical composition for the prevention or treatment of pulmonary fibrosis.

12. Use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as a functional health composition for the prevention or improvement of pulmonary fibrosis.